Full Text View
Tabular View
Study Results
Related Studies
Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study has been completed.
Study NCT00868231   Information provided by Almirall, S.A.

First Received on March 23, 2009.   Last Updated on August 14, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
COPD
Additional conditions recognized in this trial
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
More general conditions related to this trial
Respiratory Tract Diseases
Interventions listed in this trial
Aclidinium bromide 400 μg bid
Tiotropium 18 μg once-daily
Placebo
Additional drug interventions recognized in this trial
Bromides
Tiotropium
More general drug interventions related to this trial
Anti-Asthmatic Agents
Anticonvulsants
Autonomic Agents
Bronchodilator Agents
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Parasympatholytics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
Almirall, S.A.
Forest Laboratories


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services